Grifols Announces FDA Approval Of Alphanate(R) To Treat Von Willebrand Disease

... Grifols S.A., a global healthcare company specializing in the research, development and production of biologic therapies derived from human plasma, today announced that it has received approval from the US Food and Drug Administration (FDA) to market Alphanate(R) for the treatment of congenital von Willebrand Disease (VWD) in connection with surgery or other invasive procedures. [click link for full article] ...